Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560281 | 0.87 | LDHA (0.65) | LDHACYP1A2GAACYP2C9PKM | |
| SCHEMBL5411510 | 0.84 | MTNR1A (0.45) | LDHACYP1A2GAACYP2C9PKM | |
| SCHEMBL22209161 | 0.82 | TDP1 (0.43) | LDHACYP2C19PARP10KMT2AMEN1 | |
| SCHEMBL2585126 | 0.82 | LDHA (0.52) | LDHACYP1A2PARP10PPARGPPARA | |
| SCHEMBL2052852 | 0.82 | ATM (0.45) | LDHACYP1A2GAAPKMPARP10 | |
| SCHEMBL4564099 | 0.79 | LDHA (0.52) | LDHACYP1A2GAACYP2C9PKM | |
| SCHEMBL6380944 | 0.79 | LDHA (0.62) | LDHACYP1A2GAACYP2C9PKM | |
| SCHEMBL10335497 | 0.79 | LDHA (0.52) | LDHACYP1A2GAACYP2C9PKM | |
| SCHEMBL10970589 | 0.79 | LDHA (0.52) | LDHACYP1A2GAACYP2C9PKM | |
| SCHEMBL11884465 | 0.78 | PARP10 (0.45) | CYP1A2GAACYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105722556-A | Improved antiperspirant compositions | 里曼贸易有限责任公司 | 2016-06-29 | — | — | CN | claimed |
| CN-104490789-A | Pellets Comprising An Active Substance Matrix Resistant To Gastric Juice | EVONIK ROEHM GMBH | 2015-04-08 | — | — | CN | claimed |
| EP-1587497-B1 | METHOD FOR PRODUCING AN IMMEDIATELY DECOMPOSING ORAL FORM OF ADMINISTRATION WHICH RELEASES ACTIVE INGREDIENTS | EVONIK ROEHM GMBH (DE) | 2014-11-12 | — | — | EP | claimed |
| US-20130071475-A1 | Method For Producing An Oral Pharmaceutical Form With Immediate Disintegration And Active Ingredient Release | ROEHM GMBH (DE) | 2013-03-21 | — | — | US | claimed |
| US-8216613-B2 | Drugs embedded in anionic acrylic acid-methacryilc acid copolymers; extrusion | EVONIK ROEHM GMBH (DE) | 2012-07-10 | — | — | US | claimed |
| JP-4758474-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| WO-2011076196-A1 | FRANKINCENSE AND BOSWELLIC ACIDS AS A COATING FOR STENTS AND CATHETER BALLOONS | CARDIONOVUM SP.Z.O.O. (PL) | 2011-06-30 | — | — | WO | claimed |
| CN-101626769-A | Pellets comprising an active substance matrix and a polymer coating, and a method for producing said pellets | EVONIK ROEHM GMBH | 2010-01-13 | — | — | CN | claimed |
| CN-101610755-A | Pellets comprising a matrix of active substance resistant to gastric juices | EVONIK ROEHM GMBH (DE) | 2009-12-23 | — | — | CN | claimed |
| EP-2120880-A2 | PELLETS COMPRISING AN ACTIVE SUBSTANCE MATRIX RESISTANT TO GASTRIC JUICE | Evonik Röhm GmbH (DE) | 2009-11-25 | — | — | EP | claimed |
| WO-2006116989-A2 | ALL-OVER COATING OF VESSEL STENTS | HEMOTEQ AG (DE) | 2006-11-09 | — | — | WO | claimed |
| EP-1718347-A2 | BIOCOMPATIBLE COATING, METHOD, AND USE OF MEDICAL SURFACES | Hemoteq GmbH (DE) | 2006-11-08 | — | — | EP | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1667743-A2 | BIOCOMPATIBLE, BIOSTABLE COATING OF MEDICAL SURFACES | Hemoteq GmbH (DE) | 2006-06-14 | — | — | EP | claimed |
| US-20060051412-A1 | Method for producing an immediately decomposing oral form of administration which releases active ingredients | ROEHM GMBH & CO. KG (DE) | 2006-03-09 | — | — | US | claimed |
| EP-1587497-A1 | METHOD FOR PRODUCING AN IMMEDIATELY DECOMPOSING ORAL FORM OF ADMINISTRATION WHICH RELEASES ACTIVE INGREDIENTS | Röhm GmbH & Co. KG (DE) | 2005-10-26 | — | — | EP | claimed |
| WO-2005082434-A2 | BIOCOMPATIBLE COATING, METHOD, AND USE OF MEDICAL SURFACES | HEMOTEQ GMBH (DE) | 2005-09-09 | — | — | WO | claimed |
| WO-2005032611-A2 | BIOCOMPATIBLE, BIOSTABLE COATING OF MEDICAL SURFACES | HEMOTEQ GMBH (DE) | 2005-04-14 | — | — | WO | claimed |
| WO-2004066976-A1 | METHOD FOR PRODUCING AN IMMEDIATELY DECOMPOSING ORAL FORM OF ADMINISTRATION WHICH RELEASES ACTIVE INGREDIENTS | Röhm GmbH & Co. KG (DE) | 2004-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | LDHA 2643/4885CYP1A2 4857/4885GAA 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.